Cultural Corner
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder
2
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
3
DT-120 in Anxiety and Depression: Phase 3 Efficacy and Safety Findings
4
The New Ketamine Metabolite: A Conversation With Carlos Zarate, MD; Todd Gould, MD; and Craig J. Thomas, PhD
5
